FDA Clears Victoza, But Warnings And More Studies Pose Hurdles
That FDA's approval of Novo Nordisk's Victoza (liraglutide) uses its full cadre of FDA Amendments Act-granted drug safety controls - a Risk Evaluation and Mitigation Strategy and mandatory post-marketing requirements - is not surprising, given the concern about a potential cancer risk. But it is a disappointment to investors
You may also be interested in...
US government alleged sales reps gave information to physicians to create a false or misleading impression that Victoza's boxed warning and REMS messages about medullary thyroid cancer were 'erroneous, irrelevant or unimportant.' Novo's $59m settlement includes resolution of whistleblower lawsuits alleging off-label marketing.
Investors appear upbeat about a Nov. 8 FDA advisory committee on Novo Nordisk’s next-generation insulin degludec (Tresiba), despite some concerns on the cardiovascular safety front.
Twice delayed by “complete response” letters, the drug’s approval gives Amylin a once-weekly GLP-1 analog, the longest-acting drug in its class.